|
|
Table 3. Randomized Controlled Screening Trials: Fecal Occult Blood Testing
Site
|
Population Size
|
Positivity Rate (%)
|
% Localizeda
|
Testing Interval
|
Relative Mortality Reduction
|
a% Localized = T1–3 N0 M0.
|
|
Screened
|
Control
|
|
Minnesota [6,7] |
48,000 |
Unrehydrated: 2.4% |
59 |
53 |
Annual |
33% |
|
Rehydrated: 9.8% |
|
|
Biennial |
21% |
United
Kingdom [11]
|
150,000 |
Unrehydrated: 2.1% |
52 |
44 |
Biennial |
15% |
Denmark [14]
|
62,000 |
Unrehydrated: 1.0% |
56 |
48 |
Biennial |
18% |
Sweden [1] |
27,000 |
Unrehydrated: 1.9% |
65 |
33 |
|
Not
available |
|
Rehydrated: 5.8% |
|
|
|
|
References
-
Kewenter J, Björk S, Haglind E, et al.: Screening and rescreening for colorectal cancer. A controlled trial of fecal occult blood testing in 27,700 subjects. Cancer 62 (3): 645-51, 1988.
[PUBMED Abstract]
-
Mandel JS, Bond JH, Church TR, et al.: Reducing mortality from colorectal cancer by screening for fecal occult blood. Minnesota Colon Cancer Control Study. N Engl J Med 328 (19): 1365-71, 1993.
[PUBMED Abstract]
-
Mandel JS, Church TR, Ederer F, et al.: Colorectal cancer mortality: effectiveness of biennial screening for fecal occult blood. J Natl Cancer Inst 91 (5): 434-7, 1999.
[PUBMED Abstract]
-
Hardcastle JD, Chamberlain JO, Robinson MH, et al.: Randomised controlled trial of faecal-occult-blood screening for colorectal cancer. Lancet 348 (9040): 1472-7, 1996.
[PUBMED Abstract]
-
Kronborg O, Fenger C, Olsen J, et al.: Randomised study of screening for colorectal cancer with faecal-occult-blood test. Lancet 348 (9040): 1467-71, 1996.
[PUBMED Abstract]
|
|
|